Skip to main content
OpenTrials
Completed

NCT Number: NCT05288231

Cardiac Manifestation in Adolescent After Pfizer COVID-19 Injection in Thailand

Rationale Recently, a CDC advisory Committee on Immunization Practices identified a likely association between the 2 COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna and cases of myocarditis and pericarditis. For the cardiovascular system, 4863 adverse events (AEs) were reported from the Pfizer vaccine. Common findings observed with vaccines under study were tachycardia(16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.6%), and increased heart rate (9.03%). In this study we characterized, classified, evaluate the dynamic of cardiac function and ECG abnormality after the Pfizer vaccine injection.

This is a prospective cohort study. All participants aged 13-18 years old and above who visited the second dose Pfizer covid-19 vaccine injection to determine cardiac manifestation.

Methods for analyzing research data The data will be collected from students enrollment at Kong thabbok upatham changkol kho so tho bo school and Wachirathamsatit school. The participant's history, physical exam, and laboratory data will be reviewed and data will be extracted based on the case record form (CRF). All data will be stored securely and analyzed using the SPSS® Statistics Version 23 developed by IBM®. Data entry will be carried out using coding and verification. Quantitative data will be expressed as mean with standard deviation (SD) or median (IQR) and qualitative data will be presented as a number of observations with percentage (%). Descriptive statistics will be used to summarize the baseline values and demographic data.

All p-values will be derived using the 2-tailed testing, and statistical significance will be set at 0.05 probability. All the categorical variables will be analyzed using the chi-square (x2) or Fisher's exact test whichever is appropriate. Normality of the distribution will be tested for the continuous variable using the Kolmogorov- Smirnov test. All the variables with normal distributions will be compared using the independent t-test and will be reported as mean ± standard deviation (SD). The variables that do not pass the normality test will be compared by means of the Mann-Whitney U test and will be reported as the median and interquartile range (IQR).

Completed

Looking for future studies?

Notify Me

Key information

Age range

13 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Faculty of Tropical Medicine

Bangkok, 10400, Thailand

About this study

Data Collection Methods

  • Participants' demographics will be collected at baseline using case record form.
  • Laboratory tests include: at 3 clinical visits (Baseline, Day3, Day7 and Day 14 (optional if have cardiac manifestation) after 2nd dose of Pfizer COVID-19 vaccine) 2.1. Cardiac biomarker (Troponin-T, CK-MB) 2.2. Echocardiography 2.3. ECG (Electrocardiography)

After getting approval from the Ethics Committee and before the start of the trial, the study team informed the interesting participants about the study by invitation letter with ZOOM or line meeting. Informed consent printed to the parents who interested in this project and bring to the team investigator before enrollment. A contact address and phone number will be provided for the interesting participants to call for more information about the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 13-18 years old
  • Both males and females
  • Received 1st dose Pfizer COVID-19 vaccine injection

Exclusion criteria

  • Unable to obtain written informed consent from the participants or their legal representatives
  • History of cardiomyopathy, tuberculous pericarditis, and constrictive pericarditis
  • Severe allergic reaction to COVID-19 vaccine

Treatment and study plan

Diagnostic of ECG

Diagnostic Test

All participants who enrolled in the study will be performed ECG, cardiac enzyme and echocardiography

Other names: Diagnostic of cardiac enzyme, Diagnostic of echocardiography

Primary outcomes

  1. Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at baseline

    Time frame: Day 0

    cardiac manifestation defined as sinus tachycardia, hypertension at baseline

  2. Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 3

    Time frame: Day 3

    cardiac manifestation defined as sinus tachycardia, hypertension at day 3

  3. Number and percentage of participant with cardiac manifestation after Pfizer COVID-19 vaccine injection at day 7

    Time frame: Day 7

    cardiac manifestation defined as sinus tachycardia, hypertension at day 7

Secondary outcomes

  1. Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at baseline

    Time frame: Day 0

    frequency (%) of participant with myocarditis at baseline

  2. Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 3

    Time frame: Day 3

    frequency (%) of participant with myocarditis at day 3

  3. Number and percentage of participant with Myocarditis after Pfizer COVID-19 vaccine injection at day 7

    Time frame: Day 7

    frequency (%) of participant with myocarditis at day 7

  4. Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at baseline

    Time frame: Day 0

    frequency (%) of participant with pericarditis at baseline

  5. Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 3

    Time frame: Day 3

    frequency (%) of participant with pericarditis at day 3

  6. Number and percentage of participant with pericarditis after Pfizer COVID-19 vaccine injection at day 7

    Time frame: Day 7

    frequency (%) of participant with pericarditis at day 7

  7. Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at baseline

    Time frame: Day 0

    frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at baseline

  8. Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 3

    Time frame: Day 3

    frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 3

  9. Number and percentage of participant abnormal cardiac biomarker after Pfizer COVID-19 vaccine injection at day 7

    Time frame: Day 7

    frequency (%) of participant with abnormal cardiac biomarker (Troponin and CKMB) at day 7

Sponsors and collaborators

Lead sponsor

Mahidol University

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2022
First posted
Mar 21, 2022
Registry last updated
Jun 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.